Strug­gling Io­n­is li­cens­es Bi­cy­cle Ther­a­peu­tic­s' plat­form in a bid to de­vel­op drugs that can cross blood-brain bar­ri­er

At­tempt­ing to re­bound from set­backs ear­li­er this year, Io­n­is has en­list­ed a new part­ner in a quest to cre­ate drugs that can cross the blood-brain bar­ri­er. And the tech­nol­o­gy comes from a British biotech pri­mar­i­ly known for its ef­forts in­to on­col­o­gy.

The col­lab­o­ra­tion will see Io­n­is ex­clu­sive­ly li­cense a plat­form from Bi­cy­cle Ther­a­peu­tics to de­vel­op oligonu­cleotides tar­get­ing the trans­fer­rin re­cep­tor 1, the com­pa­nies an­nounced Tues­day morn­ing. Bi­cy­cle is nab­bing $45 mil­lion up­front and an $11 mil­lion eq­ui­ty in­vest­ment from Io­n­is.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER